8-KThe WireStrategic
Agreement Terminated
Filed Apr 30, 2026 · 2mo ago · Accession 0000886163-26-000027
Plain English
Ligand Pharmaceuticals Incorporated has provided written notice to Viking Therapeutics, Inc. of its intent to terminate the TR-Beta Program under a Master License Agreement, effective May 4, 2026, due to an alleged material breach by Viking. Viking is disputing Ligand's right to terminate.
Filing details
- Company
- LIGAND PHARMACEUTICALS INC
- Ticker
- LGND
- CIK
- 886163
- Form type
- 8-K
- Filing date
- Apr 30, 2026
- Report date
- Apr 24, 2026
- Document
- lgnd-20260424.htm
- Size
- 137 KB